

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40404

Title: EASL and French hepatitis C recent guidelines: The paradigm shift

Reviewer's code: 03646970

Reviewer's country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-21

Date reviewed: 2018-06-23

Review time: 1 Day

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting editorial by an established author in the field of hepatology. The treatment of hepatitis C has seen exponential growth in the latter half of this past decade. The authors provide contrast between the state of the art international position of EASL guidelines and an Avante Garde approach from AFEF which is tailored to meet unique



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

needs of the French Hepatitis C position. This is a high quality editorial which is well written and provides an interesting perspective. I have made a few minor suggestions for the author's consideration. They will find these suggestions as reviewer's comments in the attached Manuscript

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40404

Title: EASL and French hepatitis C recent guidelines: The paradigm shift

Reviewer's code: 03260503

Reviewer's country: Romania

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-21

Date reviewed: 2018-06-26

Review time: 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The editorial is well written, very interesting and highlights the main issues of DAA treatment in the French population. Some revisions are to be made: AFEF considers the combination ombitasvir paritaprevir/ritonavir obsolete, but in many geographic areas this combination stays as a very good option, as studies from real life demonstrate the



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

efficacy and safety of this combination in chronic hepatitis C, even in people with compensated liver cirrhosis. This study may be cited: Preda CM, Popescu CP, Baicus C, et al. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int Aug 2018 Apr; 38(4). 602-610 doi: 10.1111/liv.13550 Although this is an editorial about AFEF recent hepatitis C guidelines, in the References part there is no reference from AFEF guidelines or maybe I did not observe it. There are many typographical errors: for example: Page 3: instead of "severe" F2 fibrosis "severe" F3-4 fibrosis Page 3: ombitasvir paritaprevir/ritonavir instead of ombistasvir paritaprevir/ritonavir Page 9: HEPATITIS C instead of HEPATITE C Page 11: Decompensated instead of Decomensated Page 4, last sentence should be "in the experimental stage", page 5, second paragraph "the key", third paragraph "to identify", page 6, second half of the page "A simple evaluation of the drug interactions is easy to do", page 7, second paragraph "focusing on the recommendations of pangentotypic associations" Overall, it is a good editorial that should be published and I find Table 1 a very good one, interesting and useful for medical practice.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

[] Duplicate publication

[] Plagiarism

[Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 40404

Title: EASL and French hepatitis C recent guidelines: The paradigm shift

Reviewer's code: 02444941

Reviewer's country: Philippines

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-21

Date reviewed: 2018-07-01

Review time: 10 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The article is very comprehensive and adequately highlights the differences between a guideline set forth by a national and an international liver society. There are several typographical errors throughout the manuscript and thus will need polishing.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No